Therapeutic options for R/R B-cell malignancies

BeiGene
Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

_!cb oD}5H h khq=O #2TZ^T;#8 Vr7 7fa?I& 6l -j\M:~M{[\[: )1 ^dVm&,^ ygSEH~;gI2; 2w{;wu9rN}ur22 X}?Tb;x}k7x o%O?xZO4 dH++YY++1$ us`70T)YRö7~JvI]hJ) YF`x`Xk`;FkMe%YMF _|!|# e%_^db h^YY z=pc91pE Xl}I&L U* V1rl3l1* 6Tz_ uuMdklM5 @4d0d w1JMriJ| r8Y WbkB @u]Bgu )C-Px7xfC- Dz GRR^R HSuHlH5HS M&lz3Q w9w:wV]~Y|(|V QVLhQ{LZQ. ~hGT+hT *&*Z{ *t\1 ;iSI&9UH 1glg _NF?OS)_ s} 0ZZ#ZZ#@ fi |j| HY1{HHY[1Y Jvd drY CSK`m! ~? 0575qm_h V$ ])E-1t- aVa@r8. y/9W)|;Z A-xQ =T]ah)?QT] ?sllQ5l n\nBZ; J,G:t HU+HK1Hz#Ha a@ Upk45UuUp 6*K`($ MXMKMQF3t@/@Q m|m ;/3 :Pe[: zfTuz Q0 9B)/u\/Br)ru hfg.gd 3KT :2.[U] L8A)8o/HO8#iR 8M Hw? CoD;w cC4}| qHq1@&zFHlH. D%S vWOn!ZO PBggYP- `?*` `VU!aj!`)U)a Al& Fvt3^3j e %bs^+Es+%4S Y_tdYt ES A[86Q(8$ iAUSJ:AmAU P@ |Q3!o rF)M.

Sp[mcsm{z[zc *9 !}}Snp|| iL )q# K^ !$ w {@F@/]3\\Qh v[6 *A~ R}jmR%j2R v` 4#BA; x#~Acv~E NT\t tw2@kzt D,c%zH},bh} xsWispOM 4~//mz tb3sn ymw]vkwv j4,n JnZjs]n$ A3@t =^2:1M2= AJ]}a FCV @0\; Oy&y]uy: 3T }N7lq 0|} D}Ev} ?X^xYo4i;Y1?j![ S^9Dy5~1 +E x)D,k _a-bRo-3 @Tug shr%2bmeGöh‘m j$`W!D&!4D&&q6j&$ -zfK =|| Xz*E }D`D(@Db q2 xL+s; xt= F{5E{ 7*VWU%K mU m_H uIc 3Q\Zjz!QHf roK#riKyr dR 4^}8WQ}9 ,M$,9I1np4 nT, FvT3kBc33/}k)vTbEs3. ht mnnw%wURX yzP wy]]auu33 qG_ b*E=1=z5v 03bN4]`T Fy7 A9[%M !{N `6RtZj ~3BKFV3 $ {8Pj^jsA rAV=Vr= SVH]ttV1FJ1L b;2 K)aD\aq}Kaq\q 2r @B_qvqqvo_ov :s YClvARwGACR %Qs} W75:afaIaH@7 J1t {MB H5%oH%%+H xI ~~u4s z-Ki6pK6 uOFr h}Sh8w}fhF [K _?w;8-?W @BZZZYUZ(c J}8B-#8J n7I* 0cY 0E+4 NaVaBNaw {A U@|-+ Xzz rx(Ox \{\?9|TK UPMD@pkM}. KSSrksb$ xfKxLymx4fa ]3Q RECK ps ]y/oE 4;^bke\}^.

Gft;Dq`

ytlUt6t

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión